Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A SINGLE ADMINISTRATION OF COMP360 IN PARTICIPANTS WITH TREATMENT-RESISTANT DEPRESSION

Intervention/treatment:
PSILOCYBIN (COMP360)
Medical condition:
DEPRESSION
Protocol code:
COMP 006
Control number:
275503
Status:
Active, not recruiting
Approved:
June 22, 2023
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT05711940
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Sponsor
COMPASS PATHFINDER LIMITED

Locations

Centre for Neurology Studies
Vancouver
Medical Arts Research Group
Vancouver

B.C.

Diex Recherche Sherbrooke Inc.
Québec, B.C., J1L 0H8

British Columbia

Medical Arts Health Research Centre, Kamloops
Kamloops, British Columbia, M5B 1W8
Medical Arts Research Group - Penticton
Penticton, British Columbia, V2A 5L5
Okanagan Clinical Trials
Kelowna, British Columbia, V1Y 1Z9

Ontario

Centre for Addiction and Mental Health (CAMH)
Toronto, Ontario, J1L 0H8
Chatham-Kent Clnical Trials Centre
Chatham, Ontario, V1Y 1Z9
St. Michael's Hospital
Toronto, Ontario, M5B 1W8
Did you find what you were looking for?